Background: Therapeutic plasma exchange (TPE) has been used as one of the treatment modalities of neurological diseases. Intravenous Immunoglobulin (IVIG) and Therapeutic Plasma Exchange (TPE)are treatment options in Guillain Barre syndrome (GBS). In developing countries IVIG is not easily available and it is also expensive, TPE is preferred for treatment of GBS as it is affordable. Study on TPE for GBS are scarce here. Most of the study regarding TPE in GBS has been conducted in high –income countries as it is expensive treatment modality. Reports on TPE in GBS is very scared from Bangladesh.
Materials and Methods: A retrospective analysis of TPE with a standard hemolysis equipment for the treatment of Guillain Barre syndrome (GBS) was conducted A 50 patients of GBS who received TPE conducted between January 2017 to December 2018 in the department of Transfusion Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh were analyzed. All patients had underdone at least 2 cycles of plasma exchange. Volume exchanged in each cycle was one plasma volume.
Results: Out of 50 cases there were 43 (86%) male and 7 (14%) female. Age range of patients was from 11 – 50 years. Approximately 40% improved clinically of first cycle of PE & 85% after second cycle, 95% after third cycle and 95-100% after 5 cycle. 1(2%) patient died, and 49(98%) patients survived and recovered.
Conclusion: The treatment is cost affection in Compassion to IVIG. TPE is and affection, safe and affordable treatment modality for GBS.
Doorn PAV, Ruts L, Jacob BC. Clinical feature,pathogenesis and treatment of Guillain Barre syndrome. Lancet Neurol .2008; 7: 939-50.
Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017; 2(2): CD001798.
Zafar MS, Naqash MM, Bhat TAA, Malik GM.Guillain Barre sydrome in pregnancy:an unusual case. J Family Med Prim Care .2013; 2: 90-1.
Huges RA, Rees JH. Clinical and epidemiologic features of Guillain Barre syndrome. J Infect Dis. 1997; 176(suppl 2): S92-8.
Jacobs BC, Koga M, van Rijs W, Geleijns K, van Doorn PA, Willison HJ, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain–Barré syndrome. J. Neuroimmunol. 2008; 194(1-2): 181-190.
Perera VN,Nachamkin I,Ung H,Patterson JH,McConville MJ,Coloe PJ et al. Role of the lipo-oligosaccharide core oligosaccharide in inducing anti-ganglioside antibodies. FEMS Immunol MedMicrobial. 2007; 50: 27-36.
Tharakan J, Ferner RE, Huges RAC, Winer J, Barnett M, Brown ER, et al. PE for Guillain Barre syndrome. J. Royal Soc Med. 1989; 82: 458-61.
Van MFGA. The Guillain Barre syndrome: plasma exchange or immunoglobulin intravenously. J Neurology NeurosurgPsych. 1994; 57: 33-4.
Durward WF, Burnett AAK, Watkins R, Reid JM. Plasma exchange in Guillain Barre syndrome. Br Med J.1981; 283(6294): 794.
Gross ML, Legg NJ, Lockwood MC, Pallis C. The treatment of inflammatory polyneuropathy by plasma exchange. J Neurol Neurosurg Psych. 1982; 45(8): 675-9.
Kennard C, Newland AC, Ridley A. Treatment of the Guillain Barre syndrome by plasma exchange. J Neurol Nerusurg Psych. 1982; 45(9): 847-50.
Brett RP, Gross M, Leggt NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet. 1978; 2(8099): 1100.
Harakan J, Taandon M, Maheshwari MC. Plasmapheresis in acute infective polyneuritis. J Assoc Physicians India.1982; 30(3): 155-6.
Sanchez AP, Balogun RA. Therapeutic Plasma Exchange in the Critically Ill Patient: Technology and Indications. Adv Chronic Kidney Dis. 2021; 28(1): 59-73.
Vabonesi M, Garelli S, Mosconi L, Zerbi D, Celano I. Plasma exchange as a therapy for Guillain Barre syndrome with immune complexes. Vox Sang.1981; 41(2): 74-8.
Greenwood RJ, Newsom DJ, Huges RA, Aslan S, Bowden AN, Chadwick DW, et al. Controlled trial of plasma exchange in acute inflammatory polyneuropathy. Lancet.1984; 1(8382): 877-9.
Rial D, Stark R, Swash M, Newland A. Improvement in nerve condition after plasma exchange for Guillain Barre syndrome. J Neurol Neuosurg Psychiatry. 1980; 43(12): 1147.
This work is licensed under a Creative Commons Attribution 4.0 International License.